CoChat

Managing Adverse Events With Immune Checkpoint Agents

Dadu, Ramona, Zobniw, Chrystia, Diab, Adi · 2016 · The Cancer Journal

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Immune checkpoint inhibitors (anti-cytotoxic T-lymphocyte antigen 4 and anti programmed cell death 1/programmed cell death 1 ligand antibodies) have shown impressive clinical activity in multiple cancer types. Despite achieving great clinical success, challenges and limitations of these drugs as monotherapy or various combinational strategies include the development of a unique set of immune-related adverse events (irAEs) that can be severe and even fatal. Therefore, identification of patients at risk, prevention, consistent communication between patients and medical team, rapid recognition, and treatment of irAEs are critical in optimizing treatment outcomes. This review focuses on the description of more common irAEs and provides a suggested approach for management of specific irAEs.

Overview

Integrity signals

Registry

Crossref · 10.1097/ppo.0000000000000186

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 17 references

Cited by

See all 48

Metadata

Authors
Dadu, R., Zobniw, C., & Diab, A.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
Venue
The Cancer Journal
Published
2016-03
Volume
22
Issue
2
Pages
121-129
ISSN
1528-9117 (ISSN-L)
OpenAlex
W2341285800
Cited by
48
References
17
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 5 · 2022: 1 · 2021: 3 · 2020: 3 · 2019: 9 · 2018: 11 · 2017: 10 · 2016: 2
FWCI
5.76
Type
journal article
Language
en
Open access
closed
Locations
  • The Cancer Journal (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
immune-related adverse events, immune checkpoint inhibitors, CTLA-4 inhibitors, PD-1/PD-L1 inhibitors, irAE management, patient risk identification, cancer immunotherapy
MeSH terms
Antibodies, Monoclonal, Antineoplastic Agents, Humans, Neoplasms, Disease Management, Molecular Targeted Therapy, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Managing Adverse Events With Immune Checkpoint Agents. https://app.cochat.ai/papers/10.1097/ppo.0000000000000186
The paper
Dadu, R., Zobniw, C., & Diab, A. (2016). Managing Adverse Events With Immune Checkpoint Agents. The Cancer Journal. https://doi.org/10.1097/ppo.0000000000000186

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.